4-Hydroxy-N-propyl-N-isopropyltryptamine (4-HO-PiPT, Piprocin) is a
substituted tryptamine derivative which is claimed to have
psychedelic effects. It acts as a 5-HT2A receptor agonist, with an EC50 of 13.8 nM and an efficacy of 104.8% (vs 5-HT),[1] and has been sold as a
designer drug, first being identified in 2021 in
British Columbia,
Canada.[2]
4-Hydroxy-N-propyl-N-isopropyltryptamine (4-HO-PiPT, Piprocin) is a
substituted tryptamine derivative which is claimed to have
psychedelic effects. It acts as a 5-HT2A receptor agonist, with an EC50 of 13.8 nM and an efficacy of 104.8% (vs 5-HT),[1] and has been sold as a
designer drug, first being identified in 2021 in
British Columbia,
Canada.[2]